Cochrane · systematic review · CD012517
Glucocorticoid replacement regimens for treating congenital adrenal hyperplasia
Ng, SM, Stepien, KM, Krishan, A · Cochrane Database of Systematic Reviews · 2020 · Cochrane Library
Cystic Fibrosis and Genetic DisordersAMSTAR 2: not assessed
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
28
current version
GRADE rated
6
No studies
22
Included studies
NR
No studies 22 · 78.6%Ungraded 0 · 0%Very low 6 · 21.4%Low 0 · 0%Moderate 0 · 0%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
HC (13.5 mg/m²/day to 15.5 mg/m²/day): high morning dose vs high evening dose for treating CAH
Population: people with CAH
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
QoL HC (13.5 mg/m²/day to 15.5 mg/m²/day): high morning dose vs high evening dose | no estimate extracted | NR | No studies |
Androgen normalisation HC (13.5 mg/m²/day to 15.5 mg/m²/day): high morning dose vs high evening dose | no estimate extracted | 15 participants | Very low Downgraded: risk of bias, imprecision |
Prevention of adrenal crisis HC (13.5 mg/m²/day to 15.5 mg/m²/day): high morning dose vs high evening dose | no estimate extracted | NR | No studies |
Presence of osteopenia HC (13.5 mg/m²/day to 15.5 mg/m²/day): high morning dose vs high evening dose | no estimate extracted | NR | No studies |
Presence of testicular or ovarian adrenal rest tumours HC (13.5 mg/m²/day to 15.5 mg/m²/day): high morning dose vs high evening dose | no estimate extracted | NR | No studies |
Subfertility HC (13.5 mg/m²/day to 15.5 mg/m²/day): high morning dose vs high evening dose | no estimate extracted | NR | No studies |
Final adult height HC (13.5 mg/m²/day to 15.5 mg/m²/day): high morning dose vs high evening dose | no estimate extracted | NR | No studies |
HC (15 mg/m²/day) versus PD (3 mg/m²/day) versus DXA (0.3 mg/m²/day) for treating CAH
Population: people with CAH
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
QoL HC (15 mg/m²/day) vs PD (3 mg/m²/day) versus DXA (0.3 mg/m²/day) | no estimate extracted | NR | No studies |
Androgen normalisation HC (15 mg/m²/day) vs PD (3 mg/m²/day) versus DXA (0.3 mg/m²/day) | no estimate extracted | 9 participants | Very low Downgraded: risk of bias, imprecision, indirectness |
Prevention of adrenal crisis HC (15 mg/m²/day) vs PD (3 mg/m²/day) versus DXA (0.3 mg/m²/day) | no estimate extracted | NR | No studies |
Presence of osteopenia HC (15 mg/m²/day) vs PD (3 mg/m²/day) versus DXA (0.3 mg/m²/day) | no estimate extracted | NR | No studies |
Presence of testicular or ovarian adrenal rest tumours HC (15 mg/m²/day) vs PD (3 mg/m²/day) versus DXA (0.3 mg/m²/day) | no estimate extracted | NR | No studies |
Subfertility HC (15 mg/m²/day) vs PD (3 mg/m²/day) versus DXA (0.3 mg/m²/day) | no estimate extracted | NR | No studies |
Final adult height HC (15 mg/m²/day) vs PD (3 mg/m²/day) versus DXA (0.3 mg/m²/day) | no estimate extracted | NR | No studies |
HC (10 mg/m²/day to 15 mg/m²/day) versus PD (2.4 mg/m²/day to 3.5 mg/m²/day) for treating CAH
Population: people with CAH
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
QoL HC (10 mg/m²/day to 15 mg/m²/day) vs PD (2.4 mg/m²/day to 3.5 mg/m²/day) | no estimate extracted | NR | No studies |
Androgen normalisation HC (10 mg/m²/day to 15 mg/m²/day) vs PD (2.4 mg/m²/day to 3.5 mg/m²/day) | no estimate extracted | 1 study · 44 participants | Very low Downgraded: risk of bias, imprecision |
Prevention of adrenal crisis HC (10 mg/m²/day to 15 mg/m²/day) vs PD (2.4 mg/m²/day to 3.5 mg/m²/day) | no estimate extracted | NR | No studies |
Presence of osteopenia HC (10 mg/m²/day to 15 mg/m²/day) vs PD (2.4 mg/m²/day to 3.5 mg/m²/day) | no estimate extracted | NR | No studies |
Presence of testicular or ovarian adrenal rest tumours HC (10 mg/m²/day to 15 mg/m²/day) vs PD (2.4 mg/m²/day to 3.5 mg/m²/day) | no estimate extracted | NR | No studies |
Subfertility HC (10 mg/m²/day to 15 mg/m²/day) vs PD (2.4 mg/m²/day to 3.5 mg/m²/day) | no estimate extracted | NR | No studies |
Final adult height HC (10 mg/m²/day to 15 mg/m²/day) vs PD (2.4 mg/m²/day to 3.5 mg/m²/day) | no estimate extracted | 1 study · 44 participants | Very low Downgraded: risk of bias, imprecision |
HC (15 mg/m²/day) vs HC (25 mg/m²/day) with fludrocortisone (0.1 mg/day) for treating CAH
Population: people with CAH
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
QoL HC (15 mg/m²/day) vs HC (25 mg/m²/day) with fludrocortisone (0.1 mg/day) | no estimate extracted | NR | No studies |
Androgen normalisation HC (15 mg/m²/day) vs HC (25 mg/m²/day) with fludrocortisone (0.1 mg/day) | no estimate extracted | 26 participants | Very low Downgraded: risk of bias, imprecision |
Prevention of adrenal crisis HC (15 mg/m²/day) vs HC (25 mg/m²/day) with fludrocortisone (0.1 mg/day) | no estimate extracted | NR | No studies |
Presence of osteopenia HC (15 mg/m²/day) vs HC (25 mg/m²/day) with fludrocortisone (0.1 mg/day) | no estimate extracted | NR | No studies |
Presence of testicular or ovarian adrenal rest tumours HC (15 mg/m²/day) vs HC (25 mg/m²/day) with fludrocortisone (0.1 mg/day) | no estimate extracted | NR | No studies |
Subfertility HC (15 mg/m²/day) vs HC (25 mg/m²/day) with fludrocortisone (0.1 mg/day) | no estimate extracted | NR | No studies |
Final adult height HC (15 mg/m²/day) vs HC (25 mg/m²/day) with fludrocortisone (0.1 mg/day) | no estimate extracted | 26 participants | Very low Downgraded: risk of bias, imprecision |